1. Home
  2. DOOO vs MRUS Comparison

DOOO vs MRUS Comparison

Compare DOOO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOOO
  • MRUS
  • Stock Information
  • Founded
  • DOOO 1937
  • MRUS 2003
  • Country
  • DOOO Canada
  • MRUS Netherlands
  • Employees
  • DOOO N/A
  • MRUS N/A
  • Industry
  • DOOO
  • MRUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOOO
  • MRUS Health Care
  • Exchange
  • DOOO Nasdaq
  • MRUS Nasdaq
  • Market Cap
  • DOOO N/A
  • MRUS 2.7B
  • IPO Year
  • DOOO N/A
  • MRUS 2016
  • Fundamental
  • Price
  • DOOO $35.61
  • MRUS $40.90
  • Analyst Decision
  • DOOO Hold
  • MRUS Strong Buy
  • Analyst Count
  • DOOO 4
  • MRUS 14
  • Target Price
  • DOOO $53.75
  • MRUS $87.00
  • AVG Volume (30 Days)
  • DOOO 196.4K
  • MRUS 778.1K
  • Earning Date
  • DOOO 05-29-2025
  • MRUS 05-07-2025
  • Dividend Yield
  • DOOO 1.71%
  • MRUS N/A
  • EPS Growth
  • DOOO N/A
  • MRUS N/A
  • EPS
  • DOOO N/A
  • MRUS N/A
  • Revenue
  • DOOO $5,409,829,272.00
  • MRUS $54,732,000.00
  • Revenue This Year
  • DOOO N/A
  • MRUS $26.81
  • Revenue Next Year
  • DOOO $5.67
  • MRUS $23.85
  • P/E Ratio
  • DOOO N/A
  • MRUS N/A
  • Revenue Growth
  • DOOO N/A
  • MRUS 42.77
  • 52 Week Low
  • DOOO $31.78
  • MRUS $33.19
  • 52 Week High
  • DOOO $74.00
  • MRUS $61.61
  • Technical
  • Relative Strength Index (RSI)
  • DOOO 53.19
  • MRUS 45.06
  • Support Level
  • DOOO $33.04
  • MRUS $37.92
  • Resistance Level
  • DOOO $35.26
  • MRUS $46.36
  • Average True Range (ATR)
  • DOOO 1.21
  • MRUS 2.58
  • MACD
  • DOOO 0.37
  • MRUS -0.27
  • Stochastic Oscillator
  • DOOO 75.85
  • MRUS 35.31

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Share on Social Networks: